论文部分内容阅读
目的探讨经颈动脉介入化疗联合同期放化疗治疗局部晚期鼻咽癌的临床疗效及安全性。方法选择我院经病理证实的60例局部晚期鼻咽癌患者,分为介入联合同期放化疗组(A组)和同期放化疗(B组),每组30例。观察两组鼻咽癌近期疗效、治疗前后患者生存质量KPS评分变化、1年生存情况及毒副反应等。结果 A、B组总有效率均为100.0%,其中鼻咽部病灶及颈部淋巴结A组高于B组(P<0.05)。A、B组生存质量变化及1年复发率、远处转移率、无瘤生存率均无统计学差异(P>0.05)。A、B两组在白细胞、血小板减少及皮肤粘膜不良反应发生率的差异无统计学意义(P>0.05),A组在恶心呕吐及口腔黏膜不良反应方面高于B组(P<0.05)。结论介入联合同期放化疗方案治疗局部晚期鼻咽癌可提高近期疗效,1年生存率无差异,远期疗效有待进一步观察;无介入方面严重并发症,其不良反应可以耐受,具有较高的安全性。
Objective To investigate the clinical efficacy and safety of carotid artery interventional chemotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Methods Sixty patients with locally advanced nasopharyngeal carcinoma confirmed by pathology in our hospital were divided into interventional radiotherapy and chemotherapy (group A) and concurrent radiotherapy and chemotherapy (group B), with 30 patients in each group. To observe the short-term effect of two groups of nasopharyngeal carcinoma before and after treatment, KPS score changes in patients with quality of life, 1 year survival and toxicity. Results The total effective rates in group A and group B were 100.0%. The number of nasopharyngeal lesions and neck lymph nodes in group A was higher than that in group B (P <0.05). There was no significant difference in quality of life between groups A and B and the recurrence rate at 1 year, distant metastasis and tumor free survival (P> 0.05). The incidence of leukopenia, thrombocytopenia and skin and mucous membrane adverse reactions in group A and group B were not statistically different (P> 0.05). The incidence of nausea and vomiting and oral mucosal adverse reaction in group A was higher than that in group B (P <0.05). Conclusions Interventional concurrent chemoradiotherapy with adjuvant chemotherapy may improve the short-term efficacy of locally advanced nasopharyngeal carcinoma. There is no difference in 1-year survival rate and long-term efficacy needs further observation. There is no serious complications in intervention and the adverse reactions are tolerable. safety.